Blue Note Therapeutics, developed BNT200, a prescription digital therapeutic for the treatment of patients with acute myeloid leukemia (AML).
BNT200 is a device intented to treat adults with acute myeloid leukemia having anxiety and depressive symptoms, hospitalised for a regimen of high-intensity induction chemotherapy.
BNT200 is a software as a medical device (SaMD) intended for the treatment of anxiety and depressive symptoms. This digital therapeutic is designed for the patinets with inpatient setting during the 4-6 weeks associated with HIC treatment.
Every year thousands of patinets are diagnosed with AML, and manging and copying with disease symptoms is especially difficult.
Patients hospitalised after diagnosis with AML will often have sudden disruption of their life with substantial physical and psychological impacts. Therefore, the need to speed up and develop BNT200 has incresed due to the ability to lower the symptoms of distress and improve the care and quaity of life in patinets newly diagnosed with AML.
U.S. Food and Drug Administration (FDA) grants Breakthrough Device Designation for BNT200, the only digital therapeutic for acute myeloid leukemia.
